Cargando…
Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome
Opsoclonus myoclonus ataxia syndrome (OMS) is a rare neurologic syndrome. In a high proportion of children, it is associated with neuroblastoma. The etiology of this condition is thought to be immune mediated. In children, immunotherapy with conventional treatments such as corticosteroids, intraveno...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502780/ https://www.ncbi.nlm.nih.gov/pubmed/23198199 http://dx.doi.org/10.1155/2012/164082 |
_version_ | 1782250391648337920 |
---|---|
author | Alavi, Samin Kord Valeshabad, Ali Moradveisi, Borhan Aminasnafi, Ali Arzanian, Mohammad Taghi |
author_facet | Alavi, Samin Kord Valeshabad, Ali Moradveisi, Borhan Aminasnafi, Ali Arzanian, Mohammad Taghi |
author_sort | Alavi, Samin |
collection | PubMed |
description | Opsoclonus myoclonus ataxia syndrome (OMS) is a rare neurologic syndrome. In a high proportion of children, it is associated with neuroblastoma. The etiology of this condition is thought to be immune mediated. In children, immunotherapy with conventional treatments such as corticosteroids, intravenous immunoglobulin, adrenocorticotropic hormone, and even antiepileptic drugs has been tried. Recently rituximab has been used safely for refractory OMS in children with neuroblastoma. Our patient was a 3.5-year-old girl referred for ataxia and dancing eye movements starting since 1.5 years ago. She was diagnosed with neuroblastoma on imaging studies on admission. The OMS was refractory to surgical resection, chemotherapy, corticosteroids, and intravenous immunoglobulin. Patient received rituximab simultaneously with chemotherapy. The total severity score decreased by 61.1% after rituximab. Patient's ataxia markedly improved that she was able to walk independently after 6 months. Our case confirmed the clinical efficacy and safety of rituximab in a refractory case of OMS. |
format | Online Article Text |
id | pubmed-3502780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35027802012-11-29 Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome Alavi, Samin Kord Valeshabad, Ali Moradveisi, Borhan Aminasnafi, Ali Arzanian, Mohammad Taghi Case Rep Oncol Med Case Report Opsoclonus myoclonus ataxia syndrome (OMS) is a rare neurologic syndrome. In a high proportion of children, it is associated with neuroblastoma. The etiology of this condition is thought to be immune mediated. In children, immunotherapy with conventional treatments such as corticosteroids, intravenous immunoglobulin, adrenocorticotropic hormone, and even antiepileptic drugs has been tried. Recently rituximab has been used safely for refractory OMS in children with neuroblastoma. Our patient was a 3.5-year-old girl referred for ataxia and dancing eye movements starting since 1.5 years ago. She was diagnosed with neuroblastoma on imaging studies on admission. The OMS was refractory to surgical resection, chemotherapy, corticosteroids, and intravenous immunoglobulin. Patient received rituximab simultaneously with chemotherapy. The total severity score decreased by 61.1% after rituximab. Patient's ataxia markedly improved that she was able to walk independently after 6 months. Our case confirmed the clinical efficacy and safety of rituximab in a refractory case of OMS. Hindawi Publishing Corporation 2012 2012-11-06 /pmc/articles/PMC3502780/ /pubmed/23198199 http://dx.doi.org/10.1155/2012/164082 Text en Copyright © 2012 Samin Alavi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Alavi, Samin Kord Valeshabad, Ali Moradveisi, Borhan Aminasnafi, Ali Arzanian, Mohammad Taghi Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
title | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
title_full | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
title_fullStr | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
title_full_unstemmed | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
title_short | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
title_sort | clinical responses to rituximab in a case of neuroblastoma with refractory opsoclonus myoclonus ataxia syndrome |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502780/ https://www.ncbi.nlm.nih.gov/pubmed/23198199 http://dx.doi.org/10.1155/2012/164082 |
work_keys_str_mv | AT alavisamin clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT kordvaleshabadali clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT moradveisiborhan clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT aminasnafiali clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT arzanianmohammadtaghi clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome |